Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783887 | 0.85 | ESR1 (0.31) | — | |
| SCHEMBL24804934 | 0.80 | NR1I2 (0.43) | NR1I2SLC2A1 | |
| SCHEMBL19464598 | 0.80 | NR1I2 (0.43) | NR1I2SLC2A1 | |
| SCHEMBL22222931 | 0.79 | NR1I2 (0.47) | NR1I2SLC2A1LMNAADH1BADH1C | |
| SCHEMBL25150547 | 0.77 | NR1I2 (0.50) | NR1I2SLC2A1LMNA | |
| SCHEMBL19965689 | 0.77 | NR1I2 (0.38) | NR1I2SLC2A1LMNA | |
| SCHEMBL20940191 | 0.76 | NR1I2 (0.49) | NR1I2SLC2A1 | |
| SCHEMBL20372957 | 0.76 | NR1I2 (0.49) | NR1I2SLC2A1 | |
| SCHEMBL19464626 | 0.75 | NR1I2 (0.37) | NR1I2SLC2A1LMNA | |
| SCHEMBL19231993 | 0.73 | NR1I2 (0.47) | NR1I2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | NR1I2 2861/4885SLC2A1 1896/4885LMNA 4317/4885 |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | NR1I2 2861/4885SLC2A1 1896/4885LMNA 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.